Publication
Article
The American Journal of Managed Care
This second part of a 3-part supplement series to addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.
Faculty
Lori Funk, PharmD
Cape Fear Valley Health System
Fayetteville, North Carolina
Robert M. Guthrie, MD
College of Medicine and Public Health
Columbus, Ohio
Terrance Killilea, PharmD
Regence Blue Shield of Idaho
Professor Emeritus
President and Chief Executive Officer
Richmond, Virginia
Disclosure Statement
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.
These participants report relationships with the following pharmaceutical companies:
James M. McKenney, PharmD
Speaker's honoraria from:
Research grant support from:
Consulting services provided for:
The following participants have declared no financial affiliations with corporate organizations:
We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).
The American Journal of Managed Care
Signed disclosures are on file at the office of , Princeton, New Jersey.
Funding
This publication was made possible by a grant from AstraZeneca.
---
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.